Thrombosis Research
Volume 118, Issue 3 , Pages 409-416 , 2006

Low-molecular-weight heparins for the treatment of acute coronary syndrome and venous thromboembolism in patients with chronic renal insufficiency

Received 4 March 2005 ,Revised 4 March 2005 ,Accepted 8 March 2005.

References 

  1. Wharton S, Al Malki H, Crowther MA, Gangi A, Ingram AJ, Kohli S, et al. Cardiac and vascular disease and medication use in patients referred to a nephrologist with chronic renal insufficiency. Canadian Society of Nephrology. 2003 (May);[St. John's, Nfld (abstract)]
  2. Levin A, Djurdjiev O, Barrett E, Burgess E, Carlisle E, Ethier J, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis. 2001;38:1398–1407
  3. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications in patients with and without renal insufficiency. Pharmacotherapy. 2000;20:771–775
  4. Macie C, Forbes L, Foster GA, Douketis JD. Enoxaparin use in patients with an acute coronary syndrome. Prescribing practices and bleeding risk. Chest. 2004;125:1616–1621
  5. Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, et al. Influence of patient characteristics and renal function and factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2002;143:753–759
  6. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695–1702
  7. Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Haemost. 2002;28(suppl 2):3–13
  8. Boersma E, Mercado N, Poldermans D, Gardien M, Vas J, Simoons ML. Acute myocardial infarction. Lancet. 2003;361:847–858
  9. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing?. Nephrol Dial Transplant. 2001;16:1042–1046
  10. Epstein M. Aging and the kidneys. J Am Soc Nephrol. 1996;7:1106–1122
  11. Clase CM, Garg AX, Kiberd B. Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration. J Am Soc Nephrol. 2002;13:2812–2816
  12. Swedko PJ, Clark HD, Paramsouthy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med. 2003;163:356–360
  13. K/DOQI clinical practice guidelines for chronic renal disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002;39(suppl 2):S1–S46
  14. Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Haemost. 2001;27:519–522
  15. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447–452
  16. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy. 2001;21:218–234
  17. Dunn AS, Coller B. Out patient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med. 1999;106:660–669
  18. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:188S–203S
  19. Schulman S. Unresolved issues in anticoagulant therapy. J Thromb Haemost. 2003;1:1464–1470
  20. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin?. Arch Intern Med. 2002;162:2605–2609
  21. Hory B, Claudet MH, Magnette J, Bechtel P, Bayrou B. Pharmacodynamics of a very low molecular weight heparin in chronic renal failure. Thromb Res. 1991;63:311–317
  22. Cadroy Y, Pourrat Y, Baladre MF, Saivin S, Houin G, Montastruc JL, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res. 1991;63:385–390
  23. Goudable C, Saivin S, Houin G, et al. Pharmacodynamics of a low molecular weight heparin (FraxiparineR) in various stages of chronic renal failure. Nephron. 1991;59:543–545
  24. Mismetti P, Laporte-Simitsidis S, Navarro C, Sie P, D'Azemar P, Necciari J, et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low-molecular weight heparin (nadroparin). Thrombo Haemost. 1998;79:1162–1165
  25. Siguret V, Pautas E, Fevrier M, Wipff C, Durand-Gasselin B, Laurent M, et al. Elderly patients treated with tinzaparin (InnohepR) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost. 2000;84:800–804
  26. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorscheimer DA, et al. Antithrombotic therapy for coronary artery disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:513S–548S
  27. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction—2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation. 2002;106:1893–1900
  28. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809–1840
  29. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:401S–428S
  30. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688–698
  31. Douketis JD. Treatment of deep vein thrombosis: what factors determine appropriate treatment?. Can Fam Physician. 2005 (Feb);51:217–223
  32. Wells PS. Outpatient treatment of patients with deep vein thrombosis and pulmonary embolism. Curr Opin Pulm Med. 2001;7:360–364
  33. Brosa M, Rubio-Terres C, Farr I, Nadipelli V, Froufe J. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome. Pharmacoeconomics. 2002;20:979–987
  34. O'Brien BJ, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman S. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?. Am Heart J. 2000;139:423–429
  35. Rodger M, Brederson Wells PS, Beck J, Kearns B, Huebsch LB. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ. 1998;159:931–938
  36. Anderson DR, O'Brien BJ. Cost-effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism. Pharmacoeconomics. 1997;12:17–19
  37. Chong B. Heparin induced thrombocytopenia. J Thromb Haemost. 2003;1:1471–1478
  38. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial. Circulation. 1999;100:1593–1601
  39. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacodynamics and metabolism in humans. Haemostasis. 1996;26(Suppl 2):24–38
  40. Cornelli U, Fareed J. Human pharmacodynamics of low molecular weight heparins. Semin Thromb Hemost. 1999;25(Suppl 3):57–61
  41. Pedersen PC, Ostergaard PB, Hedner U, Bergqvist D, Matzsch T. Pharmacodynamics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb Res. 1991;61:477–487
  42. Barrett JS, Hainer JW, Kornhauser DM, Gaskill JL, Hue TA, Sprogel P, et al. Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers. Thromb Res. 2001;101:243–254
  43. Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Safety. 2002;25:725–733
  44. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975–982
  45. Barrett JS, Giliansky E, Hull RD, Planes A, Pentikis H, Hainer JW, et al. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther. 2001;39:431–436
  46. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins—dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995;73:630–640
  47. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000;160:181–189
  48. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153
  49. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation in patients who require temporary interruption of warfarin for an elective surgical or invasive procedure: assessment of a standardized peri-procedural anticoagulation regimen. Arch Intern Med. 2004;169:1319–1326
  50. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol. 2004;15:3192–3206
  51. Polkinghorne KR, McMahon LP, Becker GJ. Pharmacodynamic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis. 2002;40(5):990–995
  52. Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med. 1999;27(10):2224–2228
  53. Ljungberg B, Jacobson SH, Lins LE, Pejler G. Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane. Clin Nephrol. 1992;38(2):97–100
  54. Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for the treatment of venous thromboembolic disease. Ann Intern Med. 2001;134:191–202
  55. Marketing Reports. Laval, PQ, Canada: Aventis Pharmaceuticals; 2002;
  56. Busby LT, Weyman A, Rodgers GM. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol. 2001;67:54–56
  57. Antonelli D, Fares L, Anene C. Enoxaparin associated with huge abdominal wall hematomas: a report of two cases. Am Surg. 2000;66:797–800
  58. Farooq V, Hegarty J, Chandrasekar T, Lamerton EH, Mitra S, Houghton JB, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis. 2004;43:531–537
  59. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146:33–41
  60. Boneau B, Necciari J, Cariou R, Sie P, Gabaig AM, Kieffer G, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org 31540) with high affinity to antithrombin III in man. Thromb Haemost. 1995;74:1468–1473
  61. Turpie AG, Bauer KA, Eriksson BI, Lasses MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833–1840
  62. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140:867–873
  63. van Amsterdam RG, Vogel GM, Visser A, Kop WJ, Buiting MT, Meuleman DG. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times. Arterioscler Thromb Vasc Biol. 1995;15:495–503
  64. Herbert JM, Herault JP, Berant A, van Amsterdam RG, Lormeau JC, Petitou M, et al. Biochemical and pharmacologic properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood. 1998;91:4197–4220
  65. Crowther MA, Berry LR, Monagle PT, Chan AKC. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol. 2002;116:178–186

PII: S0049-3848(05)00211-2

doi: 10.1016/j.thromres.2005.03.028

Thrombosis Research
Volume 118, Issue 3 , Pages 409-416 , 2006

Article Tools